However, since 60% of SMA patients usually carry only two SMN2 copies and develop the severe form of SMA, augmenting the SMN level solely via splice correction molecules seems to be insufficient to cure SMA (Finkel et al., 2017; Mercuri et al., 2018a). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.